What happened
Broad tariffs on medical technology could undermine President Donald Trump's goals of strengthening US manufacturing and supply chains. The tariffs, which are taxes collected from American importers, can lead to higher prices, lower profits, and reduced investment. The medical technology industry, which generates over $250 billion annually and supports nearly 3 million jobs, is particularly vulnerable to these tariffs.
The industry relies heavily on imported components, and tariffs can raise the cost of these inputs. For example, a pacemaker assembled in the US with a specialized imported component would become more expensive due to the tariff. This can lead to higher costs for American manufacturers, rather than encouraging new domestic production.
The medical technology industry is also subject to strict regulations, which can make it difficult for manufacturers to adjust to changes in tariffs. The Food and Drug Administration requires approval for changes to manufacturing facilities, methods, components, and sterilization procedures, which can be a time-consuming and costly process.
The tariffs can also have a negative impact on healthcare, as medical devices are often incorporated into broader procedures paid through government reimbursement formulas. Input costs can rise faster than reimbursements adjust, leaving manufacturers and hospitals with fewer ways to absorb them.
The tariffs can also divert investment away from innovation, as every additional dollar spent paying tariffs cannot be used to finance research, equipment, or expansion. The medical technology industry invests over $20 billion annually in research and development, and the tariffs can undermine this investment.
